Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients

TORONTO, Aug. 29, 2022 /PRNewswire/ - Braxia Scientific Corp. , , a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression...

Related Keywords

Florida ,United States ,Montreal ,Quebec ,Canada ,State Of Florida ,Toronto ,Ontario ,Ottawa ,America ,Canadian ,Roger Mcintyre ,Rogers Mcintyre ,Braxia Health ,Braxia Scientific Corp ,Access To Mental Health Therapies ,Toronto The Company ,Excellence Inc ,Canadian Securities Exchange On ,Braxia Health Canada ,Health Canada ,Braxia Institute ,Canadian Rapid Treatment Center ,Access Program ,Electronic Document Analysis ,Mental Health Therapies ,Providing Ketamine ,Bipolar Disorder ,Providing Access ,Greater Toronto Area ,Assisted Therapy ,Special Access Program ,Major Depressive Disorder ,Canadian Securities Exchange ,Controlled Drugs ,Substances Act ,Restated Listing Statement ,